Sugi Predict

Sugi Predict / Compounds / SCHEMBL7188516

SCHEMBL7188516

SCHEMBL7188516

Cc1cc(C)c(C(=O)P(=O)(C(=O)c2c(C)c(C)cc(C)c2C)c2ccccc2)c(C)c1

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 5/20 0.37
▸ SMN1; SMN2 Q16637 3/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ MAPK8 P45983 1/20 0.37
▸ NPC1 O15118 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ KMT2A Q03164 8/20 0.34
▸ MEN1 O00255 7/20 0.34
▸ HPGD P15428 1/20 0.34
▸ MAPT P10636 3/20 0.34
▸ HTT P42858 2/20 0.34
▸ CFTR P13569 1/20 0.33
▸ CRHR1 P34998 1/20 0.33
▸ CRHBP P24387 1/20 0.33
▸ CRHR2 Q13324 1/20 0.33
▸ NPSR1 Q6W5P4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7180033 0.93 LMNA (0.35) LMNASMN1; SMN2ALDH1A1MAPK8NPC1
SCHEMBL7187202 0.92 LMNA (0.36) LMNASMN1; SMN2ALDH1A1MAPK8NPC1
SCHEMBL14570824 0.92 LMNA (0.36) LMNASMN1; SMN2ALDH1A1MAPK8NPC1
SCHEMBL15158 0.92 LMNA (0.40) LMNASMN1; SMN2ALDH1A1MAPK8NPC1
SCHEMBL25250816 0.91 LMNA (0.39) LMNASMN1; SMN2ALDH1A1MAPK8NPC1
SCHEMBL30988127 0.91 KMT2A (0.41) LMNASMN1; SMN2ALDH1A1MAPK8NPC1
Ammonia Solution, Strong SCHEMBL28286046 0.91 LMNA (0.40) LMNASMN1; SMN2ALDH1A1MAPK8NPC1
Lithium SCHEMBL30307090 0.91 LMNA (0.39) LMNASMN1; SMN2ALDH1A1MAPK8NPC1
Iodide SCHEMBL29831346 0.91 LMNA (0.39) LMNASMN1; SMN2ALDH1A1MAPK8NPC1
Hydrogen Sulfide SCHEMBL28313413 0.91 LMNA (0.39) LMNASMN1; SMN2ALDH1A1MAPK8NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 — — US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 — — US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 — — US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 LMNA 3241/4885SMN1; SMN2 2939/4885ALDH1A1 3416/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 LMNA 3247/4885SMN1; SMN2 3105/4885ALDH1A1 3984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.